EUVIMEDEUVIMED entdecken
Crossref

Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients

Malgorzata Mikulska iD, Chiara Sepulcri, Chiara Dentone, Federica Magne, Elisa Balletto, Federico Baldi, Laura Labate, Chiara Russo, Michele Mirabella, Laura Magnasco, Carmen Di Grazia, Chiara Ghiggi und 8 weitere

Clinical Infectious Diseases · 26.07.2023 · 77 (2) · 280-286

DOI: 10.1093/cid/ciad181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 28.03.2023. Verfasst von Malgorzata Mikulska und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Immunocompromised Host, Antiviral Agents, Antibodies, Monoclonal, COVID-19. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We aimed to evaluate efficacy and safety of combination treatment in immunocompromised COVID-19 patients.

Methods

We included all immunocompromised patients with prolonged/relapsed COVID-19 treated with combination therapy with 2 antivirals (remdesivir plus nirmatrelvir/ritonavir, or molnupiravir in case of renal failure) plus, if available, anti-spike monoclonal antibodies (mAbs), between February and October 2022. The main outcomes were virological response at day 14 (negative Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] swab) and virological and clinical response (alive, asymptomatic, with negative SARS-CoV-2 swab) at day 30 and the last follow-up.

Results

Overall, 22 patients (Omicron variant in 17/18) were included: 18 received full combination of 2 antivirals and mAbs and 4 received 2 antivirals only; in 20 of 22 (91%) patients, 2 antivirals were nirmatrelvir/ritonavir plus remdesivir. Nineteen (86%) patients had hematological malignancy, and 15 (68%) had received anti-CD20 therapy. All were symptomatic; 8 (36%) required oxygen. Four patients received a second course of combination treatment. The response rate at day 14, day 30, and last follow-up was 75% (15/20 evaluable), 73% (16/22), and 82% (18/22), respectively. Day 14 and 30 response rates were significantly higher when combination therapy included mAbs. Higher number of vaccine doses was associated with better final outcome. Two patients (9%) developed severe side effects (bradycardia leading to remdesivir discontinuation and myocardial infarction).

Conclusions

Combination therapy including 2 antivirals (mainly remdesivir and nirmatrelvir/ritonavir) and mAbs was associated with high rate of virological and clinical response in immunocompromised patients with prolonged/relapsed COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostAntiviral AgentsAntibodies, MonoclonalCOVID-19COVID-19 Drug TreatmentAntibodies, NeutralizingDrug Therapy, CombinationRecurrenceHumansMaleFemaleMiddle AgedAgedDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

anti-CD20 treatmentanti–SARS-CoV-2 monoclonal antibodieslymphomanirmatrelvir/ritonavirremdesivir

Substanzen

Antiviral AgentsAntibodies, Monoclonalcilgavimab and tixagevimab drug combinationDrug CombinationsAntibodies, Neutralizing

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Pharmacy Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Department of Health Sciences, Hygiene Unit, Ospedale Policlinico San Martino, University of Genoa, Genova, Italy.
  • Department of Internal Medicine, Clinic of Hematology, University of Genoa, Genova, Italy.

ORCID-Profile: Malgorzata Mikulska

Zitieren

APA

Mikulska, M., Sepulcri, C., Dentone, C., Magne, F., Balletto, E., Baldi, F., Labate, L., Russo, C., Mirabella, M., Magnasco, L., Di Grazia, C., Ghiggi, C., Raiola, A. M., Giacobbe, D. R., Vena, A., Beltramini, S., Bruzzone, B., Lemoli, R. M., Angelucci, E., & Bassetti, M. (2023). Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical Infectious Diseases, 77(2), 280-286. https://doi.org/10.1093/cid/ciad181

Vancouver

Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical Infectious Diseases. 2023;77(2):280-286. doi:10.1093/cid/ciad181

BibTeX
@article{Mikulska2023,
  author = {Mikulska, Malgorzata and Sepulcri, Chiara and Dentone, Chiara and Magne, Federica and Balletto, Elisa and Baldi, Federico and Labate, Laura and Russo, Chiara and Mirabella, Michele and Magnasco, Laura and Di Grazia, Carmen and Ghiggi, Chiara and Raiola, Anna Maria and Giacobbe, Daniele Roberto and Vena, Antonio and Beltramini, Sabrina and Bruzzone, Bianca and Lemoli, Roberto M and Angelucci, Emanuele and Bassetti, Matteo},
  title = {Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {2},
  pages = {280--286},
  doi = {10.1093/cid/ciad181}
}
Kostenlos starten →